Abstract
The use of thrombolytic agents for treating acute ischemic stroke is controversial. These authors report pilot data on five patients with acute ischemic stroke who were treated with half-dose recombinant tissue plasminogen activator (rt-PA) and abciximab as part of an …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
